Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making

被引:46
作者
Knight, Gwenan M. [1 ,2 ]
Dharan, Nila J. [3 ]
Fox, Gregory J. [4 ]
Stennis, Natalie [5 ]
Zwerling, Alice [6 ]
Khurana, Renuka [7 ]
Dowdy, David W. [6 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Natl Inst Hlth Res Hlth Protect, Res Unit Healthcare Associated Infect & Antimicro, London W12 0HS, England
[2] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Ctr Math Modelling, TB Modelling Grp,TB Ctr, London WC1, England
[3] Rutgers State Univ, New Jersey Med Sch, Newark, NJ 07102 USA
[4] McGill Univ, Resp Epidemiol Clin Res Unit, Montreal, PQ, Canada
[5] Bur TB Control, New York City Dept Hlth & Mental Hyg, New York, NY USA
[6] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[7] Clin Serv, Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA
基金
美国国家卫生研究院;
关键词
Models theoretical; Public health practice; Tuberculosis; MATHEMATICAL-MODELS; RANDOMIZED-TRIAL; SOUTH-AFRICA; TUBERCULOSIS; IMPACT; TRANSMISSION;
D O I
10.1016/j.ijid.2015.10.024
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The dominant approach to decision-making in public health policy for infectious diseases relies heavily on expert opinion, which often applies empirical evidence to policy questions in a manner that is neither systematic nor transparent. Although systematic reviews are frequently commissioned to inform specific components of policy (such as efficacy), the same process is rarely applied to the full decision-making process. Mathematical models provide a mechanism through which empirical evidence can be methodically and transparently integrated to address such questions. However, such models are often considered difficult to interpret. In addition, models provide estimates that need to be iteratively re-evaluated as new data or considerations arise. Using the case study of a novel diagnostic for tuberculosis, a framework for improved collaboration between public health decision-makers and mathematical modellers that could lead to more transparent and evidence-driven policy decisions for infectious diseases in the future is proposed. The framework proposes that policymakers should establish long-term collaborations with modellers to address key questions, and that modellers should strive to provide clear explanations of the uncertainty of model structure and outputs. Doing so will improve the applicability of models and clarify their limitations when used to inform real-world public health policy decisions. (C) 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 48 条
  • [1] Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing
    Anderson, Laura F.
    Tamne, Surinder
    Brown, Timothy
    Watson, John P.
    Mullarkey, Catherine
    Zenner, Dominik
    Abubakar, Ibrahim
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (05) : 406 - 415
  • [2] [Anonymous], 2013, SYST SCREEN ACT TUB
  • [3] [Anonymous], 2014, XPERT MTB RIF IMPL M
  • [4] [Anonymous], EB
  • [5] [Anonymous], 2013, Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update
  • [6] Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial
    Ayles, Helen
    Muyoyeta, Monde
    Du Toit, Elizabeth
    Schaap, Ab
    Floyd, Sian
    Simwinga, Musonda
    Shanaube, Kwame
    Chishinga, Nathaniel
    Bond, Virginia
    Dunbar, Rory
    De Haas, Petra
    James, Anelet
    Gey van Pittius, Nico C.
    Claassens, Mareli
    Fielding, Katherine
    Fenty, Justin
    Sismanidis, Charalampos
    Hayes, Richard J.
    Beyers, Nulda
    Godfrey-Faussett, Peter
    [J]. LANCET, 2013, 382 (9899) : 1183 - 1194
  • [7] How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India
    Azman, Andrew S.
    Golub, Jonathan E.
    Dowdy, David W.
    [J]. BMC MEDICINE, 2014, 12
  • [8] Complexity in Mathematical Models of Public Health Policies: A Guide for Consumers of Models
    Basu, Sanjay
    Andrews, Jason
    [J]. PLOS MEDICINE, 2013, 10 (10)
  • [9] Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
    Boehme, Catharina C.
    Nabeta, Pamela
    Hillemann, Doris
    Nicol, Mark P.
    Shenai, Shubhada
    Krapp, Fiorella
    Allen, Jenny
    Tahirli, Rasim
    Blakemore, Robert
    Rustomjee, Roxana
    Milovic, Ana
    Jones, Martin
    O'Brien, Sean M.
    Persing, David H.
    Ruesch-Gerdes, Sabine
    Gotuzzo, Eduardo
    Rodrigues, Camilla
    Alland, David
    Perkins, Mark D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (11) : 1005 - 1015
  • [10] Impact of GeneXpert MTB/RIF Assay on Triage of Respiratory Isolation Rooms for Inpatients With Presumed Tuberculosis: A Hypothetical Trial
    Chaisson, Lelia H.
    Roemer, Marguerite
    Cantu, David
    Haller, Barbara
    Millman, Alexander J.
    Cattamanchi, Adithya
    Davis, J. Lucian
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 59 (10) : 1353 - 1360